Nuvalent, Inc is a cutting-edge biotechnology company based in Cambridge, MA, specializing in the development of targeted therapies for cancer patients. With a strong focus on chemistry and structure-based drug discovery, Nuvalent designs innovative small molecules that precisely inhibit clinically proven kinase targets, addressing the challenges of resistance and selectivity.
Driven by a deep commitment to patient needs, Nuvalent collaborates with physician-scientists to identify the limitations of existing therapies and develop solutions that meet the specific requirements of cancer patients. With a dedicated team of experts in various fields, including formulation sciences, clinical operations, medicinal chemistry, and regulatory affairs, Nuvalent is passionate about utilizing their expertise to make a meaningful impact in the fight against cancer.
Generated from the website